Rosenblum Mark J 4
4 · Salarius Pharmaceuticals, Inc. · Filed Nov 20, 2025
Insider Transaction Report
Form 4
Rosenblum Mark J
Exec VP Finance, CFO
Transactions
- Purchase
Common Stock
2025-11-20$0.80/sh+20,000$16,000→ 20,177 total
Footnotes (2)
- [F1]Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.
- [F2]Includes 20 shares of unvested restricted stock granted on January 3, 2023.